Vaccines

AFP                                                                                                                     Feb. 23, 2015
Los Angeles  - Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.

Early results from an Ebola trial using the experimental drug Avigan (favipiravir) show it is somewhat effective at saving lives if given early in the illness (AFP Photo/George Frey)

The antiviral treatment is being developed by the Japanese company Toyama Chemical, and has been shown safe and effective against some other viruses including influenza, West Nile and yellow fever.

An ongoing clinical trial in Guinea is testing the drug's use in patients with the Ebola virus, which causes severe vomiting, diarrhea and sometimes fatal bleeding.

Results from only 80 people are available so far, but they show that among those who received the drug early in their illness, 15 percent died of Ebola.

Read complete story.

USA TODAY  by Liz Sazbo                                                                                  Feb. 17, 2015
The unpredictable Ebola outbreak in West Africa is thwarting health officials' best efforts both to contain the epidemic, as well as test new treatments and vaccines.

Biologist Olivier Mbaya works with serum samples from healthy volunteer participants in a European study of an experimental Ebola vaccine,, at the Vaccine Research Center at the National Institutes of Health in Bethesda, Md., Wednesday, Feb. 4, 2015. (Photo: Cliff Owen, AP)

The number of new Ebola cases has risen sharply in the West African nation of Guinea, for example, even as researchers wonder if there will be enough patients in neighboring Liberia to test experimental vaccines.

Just a few weeks ago, the number of new Ebola cases was falling in all three West African countries....

AFP                                                                                                                    Feb. 17, 2015

London--  A team of leading international scientists on Tuesday called for new Ebola vaccines to be made available in months rather than years and warned against complacency after a reduction in infection rates.

(Scroll down for link to complete report.)

"Despite falling infection rates in west Africa, the risk that the current Ebola outbreak may not be brought completely under control remains," said Jeremy Farrar, director of the Wellcome Trust, Britain's biggest medical charity.

"The accelerated development of candidate vaccines... is essential," said Farrar, who co-chairs a group of 26 international experts on vaccine development.

Read complete story.

http://news.yahoo.com/scientists-warn-against-complacency-ebola-vaccines-004937305.html;_ylt=AwrBEiHDVuNUhDcAfsPQtDMD

Recommendations for Accelerating the Development of Ebola Vaccines: Report & Analysis

CENTER FOR INFECTIOUS DISEASE AND POLICY by  Lisa Schnirring                                                      Feb. 13, 2015

Novavax yesterday announced the launch of the first human trial of its recombinant Ebola vaccine, which will make it the fourth candidate vaccine to be tested in phase 1 trials.

Novavax's product is a glycoprotein recombinant nanoparticle vaccine adjuvanted with Matrix M (Ebola GP) to boost immune response. Conducted in Australia, the study will test the safety and immunogenicity of the vaccine, with and without the adjuvant, in 230 healthy adults ages 18 to 50. Subjects will be given two intramuscular injections 3 weeks apart....

Three other Ebola vaccines are in clinical trials. Phase 2 and 3 studies of the two vaccines that are furthest along in trials got under way in Liberia at the end of January. They include two vector virus vaccines, ChAd3, developed by the National Institutes of Health (NIH) and GlaxoSmithKline (GSK), and VSV-EBOV, developed by the Canadian government and licensed by NewLink Genetics and Merck.

A phase 1 trial of a prime-boost Ebola vaccine regimen from Johnson & Johnson launched in early January in the United Kingdom.